STAT+: AbbVie purchases neuroscience developer Cerevel for $8.7 billion
STAT
DECEMBER 6, 2023
With the buyout, AbbVie will acquire several clinical-stage molecules for Parkinson’s, schizophrenia, and epilepsy, among other disorders, many of which previously belonged to one of the company’s biggest rivals. Continue to STAT+ to read the full story…
Let's personalize your content